162 results about "Cysteine l" patented technology

The invention discloses a composition for improving the stability of oleuropein in a solution as well as a preparation method and application of the composition. The composition comprises oleuropein and at least one stabilizer, and the stabilizer is selected from the group consisting of anisic acid, lactobionic acid, glycyrrhizic acid, 3, 3-thiodipropionic acid, N-acetyl-L-glutamine, propyl-cysteine and lauramidopropyl betaine; and the pH value of the aqueous solution of the composition is 4.0-8.0. The preparation method comprises the following steps: dissolving oleuropein in water, adding the stabilizer, and uniformly mixing. Through simple physical mixing, by utilizing the synergistic effect of the specific stabilizer and the oleuropein, the degradation and discoloration of the oleuropein in the storage process are remarkably inhibited. Experiments show that after the preferable composition is preserved for 30 days in an open manner, the retention rate of the oleuropein still reaches up to 80% or above, and is far superior to that of blank control and a traditional liposome wrapping method. The composition is simple and convenient in preparation process and low in cost, and provides reliable technical support for wide application of oleuropein in liquid products such as food, medicine and cosmetics.

The invention generally relates to a process for preparing a texturized plant-based food product. More specifically the invention relates to a process for preparing a texturized plant-based food product with a fibrous appearance and less plant protein off-taste having 0.1-5 wt % sugar and 0.05-1 wt % cysteine or glutathione or a combination thereof.

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.

The invention provides an application of combination of SPRC and a PD-1 or PD-L1 inhibitor in preparation of a lung cancer immunotherapy sensitizing drug, and relates to the technical field of biomedicine.In the application, through in-vitro cell experiments, cell co-culture experiments and in-vivo animal experiments, S-propargyl-L-cysteine (SPRC) can play a sensitizing role in the anti-lung cancer curative effect of the PD-1 inhibitor, and can be used for preparing a sensitizing drug for lung cancer immunotherapy. The core mechanism is as follows: 30 [mu] M SPRC is in a non-cytotoxic dose window and can specifically inhibit IFN-gamma induced STAT1 phosphorylation and PD-L1 up-regulation by depending on a CSE / H2S pathway, while IFN-gamma-STAT1-PD-L1 is a core signal axis of PD-L1 adaptive up-regulation in lung cancer cells, and the induction effect of TNF-alpha on PD-L1 is relatively weak; meanwhile, SPRC can inhibit activation of NF-kB induced by TNF-alpha and expression of inflammatory factors such as IL-6 and IL-8 through the pathway so as to exert the anti-inflammatory effect, the CD8 + T cell depletion proportion can be remarkably reduced by combining SPRC with anti-PD-1, the synergistic tumor inhibition effect is formed, the effect is verified in in-vivo and in-vitro experiments, and a closed loop of an in-vitro mechanism and an in-vivo curative effect is achieved.

The invention belongs to the technical field of biology, and relates to a bronchoalveolar lavage fluid (BALF) preserving fluid, a kit and a cytological test method. The preservation solution is composed of TCEP, N-acetylcysteine, EDTA.2Na, trehalose, Proclin300, methanol, sodium chloride and HEPES, and all the components have a synergistic effect to achieve sample viscosity removal, oxidation resistance, corrosion prevention, cell protection and pH stabilization. The preserving fluid is suitable for morphological observation and nucleic acid detection of BALF cells, and can stably preserve samples at room temperature and maintain completeness of cell membranes and clear morphological structure. The kit comprises two preparations which are mixed to form a working solution, and the working solution can be directly used for sample preservation on a sampling site. The cytological test method comprises the steps of sample collection, preservation, centrifugal slide preparation, Wright-Giemsa staining and microscopic observation. Experimental results show that preservation solutions of different formulas are compatible with a chromosome system, the cell morphology is kept stable within 3 days, the dyeing effect is good, and it is proved that the preservation system can remarkably improve the preservation stability and detection reliability of BALF samples and is suitable for cytology and molecular diagnosis application of lower respiratory diseases.

This invention discloses a NK cell culture kit, its culture method, and its application. The kit includes an amplification medium, a high-efficiency induction medium, an NK-A coating solution, an NK-B mixture, and an NK-C mixture. The amplification medium contains basal medium, NAD+, human serum albumin, transferrin, β-glucan, glutathione, β-mercaptoethanol, and linoleic acid. The high-efficiency induction medium, in addition to the amplification medium components, contains soybean peptides, nicotinamide, inulin, and N-acetyl-L-cysteine. The NK-A coating solution contains heparin sodium, monoclonal antibodies, and antibodies. The NK-B mixture contains Inbakicept, IL-2, and IL-15. The NK-C mixture contains linolenic acid, IL-2, and IL-18. The Inbakicept factor in the kit can activate NK cells and enhance their cytotoxicity; linolenic acid can inhibit T cell proliferation, increase NK cell purity, and enhance cell efficacy.

The application relates to a compound medicine for delaying skeletal muscle aging and application thereof, and the medicinal active components in the compound medicine composition are composed of menadione bisulfite sodium and N-acetyl cysteine, and belong to the technical field of biological medicine. A novel drug combination mode is developed, an oxidant menadione bisulfite sodium (MBS) and an antioxidant N-acetyl-L-cysteine (NAC) are combined and given in different time periods to regulate the H2O2 circadian rhythm of the skeletal muscle of old mice, the changes of the muscle strength, histopathology and aging marker protein level of the skeletal muscle of the old mice are detected, and then the precise compound medicine capable of improving the skeletal muscle function of the old mice and delaying skeletal muscle aging is determined. The application provides an effective drug combination strategy for relieving or treating the delay of skeletal muscle aging, and has very significant meaning.

This invention provides the application of a composition in the preparation of drugs for osteoarthritis, belonging to the field of arthritis technology. The composition comprises tofu glycosides, N-acetylcysteine, seaweed peptides, and PDGF. The combination of these drugs significantly enhances the chondrogenic differentiation and migration capacity of chondrocyte stem cells under inflammatory conditions. Furthermore, in an SD rat knee osteoarthritis model, chondrocyte stem cells treated with the enhanced culture medium reduced the Wakitani histological score from 8.83 to 2.17±0.98, demonstrating a superior repair effect compared to traditional methods. Therefore, this invention provides a foundation for the efficient treatment of osteoarthritis.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

The application provides a preparation method of a composite water-retaining agent and application of the composite water-retaining agent in fermented meat products. The composite water-retaining agent is composed of a basic water-retaining agent and water-retaining microspheres. Components of the basic water-retaining agent include glutamine transaminase, trehalose, L-histidine and gellan gum, and the basic water-retaining agent plays a water-retaining role in a curing period; the water-retaining microspheres are prepared by embedding L-cysteine and reduced glutathione in Pediococcus pentosaceus fermented pineapple leaves as wall materials and vehiclepsin seed gum, and slowly release active substances under acid triggering in a late fermentation period, thereby playing a water-retaining role. The application provides a non-phosphorus composite water-retaining agent with better comprehensive performance than composite phosphate and commercial non-phosphorus water-retaining agents, significantly improves water-retaining property without interfering with fermentation, and provides a green, efficient and non-phosphorus special water-retaining solution for fermented meat products.

The invention relates to the technical field of medicines, in particular to a preparation process of xantinol nicotinate injection and an impurity control method of the xantinol nicotinate injection. According to the process, water for injection is subjected to nitrogen deoxidation treatment, a whole-process nitrogen-sealed environment is maintained, xantinol nicotinate is gradually added in three times, and a multi-component synergistic stable system including hydroxypropyl-beta-cyclodextrin, N-acetyl-L-cysteine, L-methionine, diethylenetriamine pentaacetic acid, sodium metasulfite, sodium thiosulfate and the like is matched, so that the xantinol nicotinate injection is prepared. Double-molecular-weight dextran is introduced to regulate and control a microenvironment, an acetic acid-sodium acetate buffer system is introduced to optimize pH, and finally, high stability and low impurity generation of the finished injection at high temperature are realized through nitrogen replacement subpackaging and precise sterilization conditions. According to the method, the content and the purity of the xantinol nicotinate injection are remarkably improved, the impurity content during sterilization and storage is remarkably reduced, the safety and the effectiveness of drugs are guaranteed, and the method has important significance on optimization of a heat-sensitive injection process.

The invention relates to a composition comprising N-acetylcysteine (NAC) for use in the prevention and / or treatment of at least one adverse effect of a chemotherapy in the treatment of cancer. It is characterized in that it further comprises vitamin B12 and / or a combination of vitamins B1, B2 and B3. The invention more particularly relates to the use of said composition for the prevention and / or treatment of chemo-induced nociceptive and / or neuropathic pain.

A composition for relieving hangovers and protecting the liver, made from the following raw materials in the indicated weight ratios: 3-20 parts of kudzu root extract, 2-20 parts of Japanese raisin tree fruit extract, 1-12 parts of N-acetylcysteine, 1-12 parts of L-ornithine, 1-15 parts of L-glutamine, 0.2-8 parts of glycyrrhetinic acid glycyrrhiza extract, 0.05-5 parts of curcumin, 0.005-0.5 parts of piperine, 0.5-10 parts of vitamin C, 0.01-2 parts of B vitamins complex, 0.1-8 parts of electrolyte salts, and 1-25 parts of honey or oligosaccharides.

The application provides a kind of nasal mucosa in vitro culture method and culture fluid, the composition of the culture fluid includes Wnt / β-catenin signal pathway activator 0.1-20 μg / ml, fibroblast growth factor 10-150 ng / ml, TGF-β inhibitor 0.02-3 μg / ml, ROCK inhibitor 0.1-100 μmol / L, P38 MAPK inhibitor 0.1-1 μmol / L, serum-free additive 1X, N-acetyl cysteine 1-10 mmol / L, nicotinamide 1-20 mmol / L, GlutaMax additive 1X, antibiotic, DMEM / F12 culture medium 1X.The application can carry out in vitro culture to nasal mucosa, can keep at least 2 weeks of activity, and have complete epithelial barrier and immune system, can realize ex vivo nasal mucosa virus infection experiment.

The invention discloses a dual-modified filler for deep denitrification of a micro-polluted water body and a preparation method and application thereof. The preparation method of the dual-modified filler comprises the following steps: S1, an oxidation / reduction protein grafting step: soaking a filler in an acidic potassium permanganate solution for oxidation treatment, and flushing the surface of the filler with an acidic solution; or soaking the filler in an L-cysteine solution for reduction treatment; washing the oxidized / reduced filler to be neutral, respectively soaking the filler in a glutaraldehyde solution and a protein solution, fully washing the filler with water after soaking is completed, and airing the filler for later use; s2, cation loading: soaking the filler subjected to the step S1 in an inorganic cation solution, then taking out the filler, and heating to dry the filler, so that inorganic cations are loaded on the surface of the filler. The filler is subjected to dual modification through oxidized / reduced protein grafting and cation loading, so that the biocompatibility and specific surface area of the filler are remarkably improved, the biofilm culturing time is shortened, and the denitrification effect is improved.

A micronutrient composition comprises of several combinations of individual ingredients in forming Mix 11, G12, G13 and core mix formulation. Core mix contains magnesium citrate, alpha-Ketoglutaric acid, L-Citrulline and Taurine. The Mix 11, G12 and G13 contains Magnesium Citrate, Alpha-Ketoglutaric Acid, Niacinamide, L-Glutamine, L-Citrulline, Sodium Pyruvate, Succinic acid, Vitamin B complex, Taurine, L-Cysteine, L-Methionine, L-Ascorbic Acid, Coenzyme Q10 or combination thereof. A method of administering and treating a specific disease which is due to one of an oxidative stress, impaired mitobiogenesis and ATP production in a mammal is disclosed.

The present invention is characterized by being a novel sulforaphane derivative comprising a complex of sulforaphane (1-isothiocyanato-4-[methylsulfinyl]butane (SFN)) and cysteine persulfide (CysSnH, n=2, 3, 4, or 5) or glutathione persulfide (GSnH or GSnG, n=2, 3, 4, or 5).

The application belongs to the technical field of medicine, and specifically discloses a kind of nasal spray composition and nasal spray and application, the nasal spray composition includes the following components: hyaluronic acid, trehalose, N-acetyl-L-cysteine, methylene succinic acid, gallic acid, taurine, coenzyme Q10, rosemary essential oil.The nasal spray composition provided by the application is accurately adjusted, can give full play to the advantages of each component, provide better nasal ventilation and humidity.The nasal spray composition provided by the application can inhibit the excessive activation of LPS-induced neutrophil Netosis in vitro culture and the excessive activation of LPS-induced mouse airway neutrophil Netosis, thereby reducing the inflammatory response in the nasal cavity.

The invention discloses a synergistic feed additive for preventing and treating fatty liver diseases of laying fowls. The feed comprises the following components: 15%-25% of bile acid; 10%-20% of lysolecithin; 5%-15% of L-L-carnitine; 15%-25% of N-acetylcysteine (NAC); 10%-20% of a rosmarinic acid extract; 1%-3% of selenium yeast; and the balance of carrier. Wherein the carrier is one or more of water-soluble silicon dioxide, expanded rice hull powder and calcium hydrophosphate. According to the technical scheme, the feed additive composition containing multiple components of L-carnitine and having a multi-target synergistic effect can efficiently prevent and treat fatty liver diseases of laying fowls by simultaneously acting on a plurality of key links (intestinal burden reduction, liver delivery, mitochondrial oxidation and antioxidant protection) of fat metabolism.

An immunomodulatory composition comprising an active agent, said active agent comprising acetylcysteine and beta-glucan.

The application belongs to the field of enzymes and particularly relates to a mutant of glutamyl cysteine dipeptide ligase, a coding gene of the mutant, a recombinant plasmid, a recombinant microorganism and application, wherein the amino acid sequence of the mutant is an amino acid sequence with at least one mutation of T84V, S27A, L128K and A691S in the wild amino acid sequence shown in SEQ ID NO. 1. Researches of the application show that the catalytic activity of the enzyme can be significantly enhanced by the mutation of the specific sites in the wild type sequence of SEQ ID NO. 1, and the reaction conversion yield can be effectively improved when the enzyme is used for the catalytic synthesis of gamma-glutamyl cysteine dipeptide.

The invention relates to a non-therapeutic computer system configured to perform a performance optimization method, which comprises the steps of: a) Providing a sample from a subject who exercises and does not experience adverse effects from exercise; b) Measuring ex vivo the concentration of one or more metabolites from the group comprising or consisting of citrate, alpha-hydroxybutyrate, beta-hydroxybutyrate, and L-cysteine ​​in the provided sample to obtain a baseline or baselines; c) Providing a sample from the same subject as in a), after the intensity, frequency, and / or volume of the subject's exercise has increased, or when the subject experiences adverse effects from exercise; d) Measuring ex vivo the concentration of the same metabolite as in b); e) Determining the deviation of the concentration in d) from the baseline;f) Optimize exercise intensity / volume, exercise frequency and / or exercise volume, based on the deviation(s) in e), where, as applicable, deviation(s) of any of the metabolite concentrations from baseline values ​​amounting to an increase of at least 10% for citrate, an increase of at least 15% for alpha-hydroxybutyrate, an increase of at least 15% for beta-hydroxybutyrate and below 95% of the baseline value for L-cysteine, indicates that exercise intensity or exercise frequency should be reduced.;

The application discloses a medicine composition for promoting wound healing and a preparation method and application thereof. The medicine composition comprises the following components in parts by weight: 1-10 parts of hemoglobin molecules, 1-5 parts of lipoic acid, 0.1-1 part of acetylcysteine, and 40-80 parts of a solvent; the hemoglobin molecules comprise at least one cysteine part and at least one histidine part, wherein the cysteine part comprises an acetyl group or an ethyl maleoyl group, and the histidine part comprises a benzimidazole derivative group. The application applies lipoic acid and acetylcysteine to the external medicine composition of the hemoglobin molecules modified by acetyl groups or ethyl maleoyl groups in combination, effectively relieves the irritant reaction caused by the hemoglobin modification to the skin through the synergistic antioxidant and tissue protection effects, and thus improves the safety and applicability of the medicine composition in skin wound treatment, and the medicine composition is suitable for treating multiple types of wounds such as external injuries, burns, postoperative wounds and ulcer wounds.

For the purpose of determination for the selection of intravesical BCG instillation therapy, the present invention comprises measuring 2-ethylhydracrylic acid-2, arabinonic acid-2, carnitine, lauric acid, myristic acid, octanoylcarnitine, paraxanthine, S-methylcysteine, S-methylcysteine-S-oxide, SDMA, theobromine, indole-3-acetic acid, pentanoic acid, 1-methyl-4-imidazoleacetic acid, ADMA, alanine, argininosuccinic acid, choline, citrulline, creatinine, guanidoacetic acid, lysine, methionine sulfoxide, myristic acid, N-(1-deoxy-1-fructosyl)leucine, N-acetylneuraminic acid, N6,N6,N6-trimethyllysine, propionylcarnitine, threonine, gamma-glutamyl-glycine, gamma-glutamyl-tyrosine, and gamma-glutamyl-valine in blood, serum, or plasma.

The application belongs to the technical field of biological medicine, and discloses an oxidation-reduction response type nanoparticle as well as a preparation method and application thereof. The nanoparticle takes a cationic lipid compound and an amphiphilic block polymer containing a disulfide bond as a composite carrier, and co-encapsulates active ingredients siPD-L1 and N-acetyl cysteine. The nanoparticle can be responsively disintegrated in a high-reduction microenvironment of a tumor, synchronously release the two active ingredients, realize the dual effects of reversing immunosuppression and scavenging active oxygen respectively, and synergistically inhibit the growth and metastasis of residual tumors after radiofrequency ablation of liver cancer. The preparation process is simple, the nanoparticle has good stability, high targeting and high biological safety, and provides a new effective strategy for the treatment of residual tumors after radiofrequency ablation of liver cancer.

Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.

The invention discloses a manganese-doped carbon dot and a preparation method and application thereof.The preparation method comprises the steps that citric acid is dissolved in deionized water, then MnCl2. 4H2O, ethanediamine and N-acetylcysteine are sequentially added and fully dissolved, and a hydrothermal reaction is conducted to obtain the small-particle-shaped manganese-doped carbon dot. According to the invention, the inorganic substance MnCl2. 4H2O which is widely anti-inflammatory and anti-oxidation is utilized to participate in the preparation of the carbon dots through a simple hydrothermal synthesis method, and the obtained manganese-doped carbon dots have the advantages of excellent multi-enzyme activity, good biocompatibility and the like, and have good application prospects in the aspects of inflammatory enteritis, colitis recovery and the like.

A disease risk assessment apparatus (100) includes an assessment unit (1) for assessing the risk of developing dementia in a subject, based on the concentration of an amino acid in the blood of the subject. The amino acid includes at least one selected from the group consisting of histidine, phenylalanine, leucine, isoleucine, methionine, threonine, glycine, glutamine, lysine, asparagine, homocysteine, cystathionine, S-adenosylmethionine, and S-adenosylhomocysteine.